A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)

Haruyasu Murakami, Nobuyuki Yamamoto, Taro Shibata, Koji Takeda, Yukito Ichinose, Yuichiro Ohe, Noboru Yamamoto, Yuichiro Takeda, Shinzoh Kudoh, Shinji Atagi, Miyako Satouchi, Katsuyuki Kiura, Naoyuki Nogami, Masahiro Endo, Hirokazu Watanabe, Tomohide Tamura

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objectives: We conducted an open-label, multicenter, single-arm study to confirm the efficacy and safety of amrubicin (AMR), a topoisomerase II inhibitor, for treating refractory small-cell lung cancer (SCLC). Patients and methods: Patients with chemotherapy-refractory SCLC received 40mg/m2 AMR for 3 consecutive days, every 21 days. The primary endpoint was the overall response rate (ORR) and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety. Results: Between November 2009 and February 2011, 82 patients were enrolled. Each patient received a median of four treatment cycles (range, 1-22 cycles). ORR was 32.9% [. P<. 0.0001 by the exact binomial test for the null hypothesis that ORR. ≤. 10%; 95% confidence interval (CI), 22.9-44.2%]. The median PFS and OS periods were 3.5 months (95% CI, 3.0-4.3 months) and 8.9 months (95% CI, 7.6-11.3 months), respectively. Significant differences in ORR (21.4% v 45.0%; P= 0.034), PFS (median, 2.9 v 5.1 months; P= 0.0009), and OS (median, 7.9 v 13.1 months; P= 0.0128) were observed between patients previously treated with etoposide and others. Neutropenia was the most common grade 3 or 4 adverse events (93.9%), and febrile neutropenia developed in 26.8% patients. No treatment-related death occurred. Conclusions: AMR monotherapy can be considered an effective and safe treatment option for refractory SCLC. Previous chemotherapy with etoposide may influence AMR efficacy.

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalLung Cancer
Volume84
Issue number1
DOIs
Publication statusPublished - Apr 2014

Keywords

  • Amrubicin
  • Chemotherapy
  • Etoposide
  • Phase II
  • Refractory
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)'. Together they form a unique fingerprint.

  • Cite this

    Murakami, H., Yamamoto, N., Shibata, T., Takeda, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Takeda, Y., Kudoh, S., Atagi, S., Satouchi, M., Kiura, K., Nogami, N., Endo, M., Watanabe, H., & Tamura, T. (2014). A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer, 84(1), 67-72. https://doi.org/10.1016/j.lungcan.2014.01.012